ArticleInternational journal of hematology2009
Involvement of SRC-3 in deguelin-induced apoptosis in Jurkat cells.
Article in International journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- The Role of Nutraceuticals in Chemoprevention and their Therapeutic Effects when used in Combination with Synthetic Drugs.Current medicinal chemistry · 2025Review
- Deguelin's Anticancer Bioactivity: Challenges and Opportunities in Medicinal Chemistry.Frontiers in pharmacology · 2025Review
- Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.Nature communications · 2021Article
- Article
- Increased radiosensitivity and radiation-induced apoptosis in SRC-3 knockout mice.Journal of radiation research · 2014Article
- Impaired hematopoiesis and delayed thrombopoietic recovery following sublethal irradiation in SRC‑3 knockout mice.Molecular medicine reports · 2014Article
- Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention.Molecular and clinical oncology · 2013Review
- SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization.Genes & development · 2013Article
- SRC-3 has a role in cancer other than as a nuclear receptor coactivator.International journal of biological sciences · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to investigate the anticancer effects and the molecular mechanisms of deguelin on Jurkat cells. Cell viability was assessed by MTT assay. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) assay and transmission electron microscopy were used to detect cell apoptosis. A propidium iodide method was used to study cell cycle distribution. RT-PCR and Western blotting were employed to assess the expression levels of steroid receptor coactivator-3 (SRC-3), nuclear factor-kappaB (NF-kappaB) and some apoptosis related genes, including Bcl-2 and Bcl-xL. Deguelin was able to inhibit cell proliferation by a cell-cycle arrest in the G(1)/G(0) phase and induce apoptosis in Jurkat cells in vitro, with a 24-h IC(50) value of 43.73 +/- 0.35 nmol/L. The antileukemia effect of deguelin might be correlated well with the downregulation of the expression of SRC-3 and its related transcription factor NF-kappaB, which thus influenced the expression of apoptosis related genes Bcl-2 and Bcl-xL. Deguelin presented potent effects on growth arrest and apoptosis induction in Jurkat cells in vitro via the interruption of SRC-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.